Stockscreener 앱 받기
44.76
2.23%
-1.0788
Guardant Health Inc 주식(GH)의 최신 뉴스
Liquid Biopsy Market Insights and Projections 2025-2032 - openPR
VA expands coverage to include CRC blood test for veterans - Investing.com India
Guardant Health shares rise on VA coverage for cancer test - Investing.com
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries - Yahoo Finance
Key Market Driver in Breast Cancer Liquid Biopsy Industry 2025: Rising Breast Cancer Cases Fuel Demand For ... - WhaTech
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health director Tariq Musa sells $5,069 in stock By Investing.com - Investing.com South Africa
Guardant Health director Tariq Musa sells $5,069 in stock - Investing.com India
AI Healthcare Co. Accuses Test-Maker Of Infringing Patents - Law360
AI Health Care Co. Accuses Test-Maker Of Infringing Patents - Law360
Creating awareness for Colorectal Cancer Month - WFLA
Guardant Accused of Infringing Tempus AI Cancer Research Tech - Bloomberg Law
Liquid biopsy market flooded with opportunity - BioWorld Online
Guardant Health rises after Medicare ADLT status for colorectal cancer test - MSN
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation - Seeking Alpha
Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics By Investing.com - Investing.com UK
Guardant Health’s ADLT Status Boosts Shield CRC Test’s Market Position and Financial Outlook - TipRanks
1,415 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by SBI Securities Co. Ltd. - Defense World
Investing in Guardant Health (NASDAQ:GH) a year ago would have delivered you a 129% gain - Simply Wall St
Raymond James maintains Guardant Health stock at Outperform By Investing.com - Investing.com Canada
Guardant Health gains ADLT status for CRC blood test By Investing.com - Investing.com Canada
Guardant Health, Inc. Receives ADLT Status From CMS for Shield Blood Test -March 11, 2025 at 07:00 am EDT - Marketscreener.com
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue - Benzinga
Sector Update: Health Care -March 11, 2025 at 01:38 pm EDT - Marketscreener.com
Sector Update: Health Care - TradingView
Guardant Health stock up on Medicare ADLT status (GH:NASDAQ) - Seeking Alpha
Guardant Health Shares Soar After Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 11:01 am EDT - Marketscreener.com
Citi maintains Buy on Guardant Health, price target at $60 By Investing.com - Investing.com UK
Guardant Health Receives ADLT Status From CMS for Shield Blood Test - 01Net
Guardant Health Says Colorectal Cancer Test Granted ADLT Status -March 11, 2025 at 08:48 am EDT - Marketscreener.com
Guardant Health gains ADLT status for CRC blood test - Investing.com India
Guardant Health Receives ADLT Status From CMS For Shield Blood Test -March 11, 2025 at 07:19 am EDT - Marketscreener.com
When the Price of (GH) Talks, People Listen - Stock Traders Daily
FDA approves blood test for colon cancer detection - MSN
Bank of New York Mellon Corp Reduces Stock Holdings in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock - Defense World
Principal Financial Group Inc. Has $308,000 Stake in Guardant Health, Inc. (NASDAQ:GH) - Defense World
Guardant Health Base Business in 'Fundamentally Good Shape,' Morgan Stanley Says - Marketscreener.com
Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.
Guardant Health, Inc. (NASDAQ:GH) Short Interest Update - Defense World
Lung Cancer Diagnostics Market Growth | Trends, Size & Forecast 2025-2033 | DSS Imagetec, Abbott, Guardant Health. - openPR
Guardant Health director Joyce sells $4,271 in stock - Investing.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight - Investing.com India
Guardant Health director Joyce sells $4,271 in stock By Investing.com - Investing.com UK
Guardant Health price target raised to $52 from $42 at Morgan Stanley - TipRanks
LSUHS partners with Dak Prescott to boost colon cancer screening - KTALnews.com
Morgan Stanley raises Guardant Health target to $52, maintains Overweight By Investing.com - Investing.com UK
Morgan Stanley Adjusts Price Target on Guardant Health to $52 From $42, Keeps Overweight Rating - Marketscreener.com
Guardant Health at TD Cowen Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities - The Bakersfield Californian
Commit To Buy Guardant Health At $32, Earn 17.9% Annualized Using Options - Nasdaq
Guardant Health Financial Report: Q4 2024 Revenue Surpasses ExpectationsNews and Statistics - IndexBox, Inc.
Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue - Yahoo Finance
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Analysts - Defense World
ARK Investment Management LLC Has $43.99 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
0.37%
0.10%
자본화:
|
볼륨(24시간):